AMPLO BIOTECHNOLOGY
Diseases of the neuromuscular junction have profound health effects including paralysis, breathing and swallowing difficulties. Amplo Biotechnology plans to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction with an initial focus on congenital myasthenic syndromes. Amplo’s lead program, AAV-Dok7, was developed by Professor Yuji Yamanashi's group of the Institute of Medical Science at the University of Tokyo, and is applicable to multiple rare, severe diseases.
AMPLO BIOTECHNOLOGY
Industry:
Biotechnology Health Care Neuroscience Therapeutics
Founded:
2019-01-01
Address:
Pompano Beach, Florida, United States
Country:
United States
Website Url:
http://www.amplobiotechnology.com
Status:
Active
Email Addresses:
[email protected]
Total Funding:
2.24 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Google
Current Advisors List
Current Employees Featured
Founder
Investors List
National Institutes of Health (NIH)
National Institutes of Health (NIH) investment in Grant - Amplo Biotechnology
Official Site Inspections
http://www.amplobiotechnology.com
Unable to get host informations!!!
